About Handl Therapeutics
Handl Therapeutics is a Healthcare company based in Leuven (Belgium) founded in 2019 by Michael Linden, and was acquired by UCB in November 2020. Developer of gene therapy to treat neurodegenerative diseases. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Diversified.
Company details
Handl Therapeutics was founded in 2019 and is headquartered in Leuven, Belgium. Focus is placed on the development of in vivo gene therapies targeting central nervous system diseases. Proprietary adeno-associated virus capsid technology is utilized to address neurodegenerative conditions. Operations center on advancing therapeutic solutions within the biotechnology sector, with emphasis on clinical and preclinical research for CNS applications.
- Headquarters Leuven, Belgium
- Founders Michael Linden
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website handltherapeutics.com
- Social LinkedIn
- Acquired by UCB (Nov 2020)
Funding Insights of Handl Therapeutics
- Total Rounds 1
- Last Round Grant — $3.56M
- First Round $3.56M
(Sep 2020)
- Investors Count 1
All 1 funding rounds of Handl Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $3.56M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Handl Therapeutics
Handl Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include UCB and VLAIO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Management consulting services are provided to businesses in Belgium. | 2003 | vlaio.be | Brussels, Belgium | |
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium |
Investor details for Handl Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Handl Therapeutics
1 people are tracked at Handl Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Linden | Founder | Leadership |
Complete people profiles for Handl Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Handl Therapeutics
3 dated milestones of Handl Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Handl Therapeutics is founded.
- Funding First funding round of $3.6M.
- Exit Acquired by UCB.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Handl Therapeutics
Complete news archive for Handl Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Handl Therapeutics
Handl Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Handl Therapeutics is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.
Handl Therapeutics was founded in 2019 and is headquartered in Leuven, Belgium. Focus is placed on the development of in vivo gene therapies targeting central nervous system diseases. Proprietary adeno-associated virus capsid technology is utilized to address neurodegenerative conditions. Operations center on advancing therapeutic solutions within the biotechnology sector, with emphasis on clinical and preclinical research for CNS applications.
Yes. Handl Therapeutics was acquired by UCB in November 2020.